Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NTRK”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06390852
What this trial is testing

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Not applicableNo Longer AvailableNCT03066661
What this trial is testing

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Who this might be right for
Cancers With NTRK, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Testing effectiveness (Phase 2)Ended earlyNCT04617054
What this trial is testing

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Who this might be right for
Solid Tumor
Nuvation Bio Inc. 14
Early research (Phase 1)Study completedNCT03215511
What this trial is testing

Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 81
Not applicableNo Longer AvailableNCT03206931
What this trial is testing

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer
Testing effectiveness (Phase 2)Active Not RecruitingNCT02637687
What this trial is testing

Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 154
Testing effectiveness (Phase 2)Ended earlyNCT02920996
What this trial is testing

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungSolid Tumor
Dana-Farber Cancer Institute 12
Early research (Phase 1)Ended earlyNCT03182257
What this trial is testing

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Who this might be right for
Solid Tumor
Ono Pharmaceutical Co. Ltd 1
Early research (Phase 1)Study completedNCT06529445
What this trial is testing

Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

Who this might be right for
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Jiangsu vcare pharmaceutical technology co., LTD 84
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more
St. Jude Children's Research Hospital 139
Testing effectiveness (Phase 2)Looking for participantsNCT07394374
What this trial is testing

CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

Who this might be right for
Solid Tumors Harboring NTRK FusionNTRKNTRK Gene Fusion+1 more
Cullgen (Shanghai),Inc 42
Early research (Phase 1)Study completedNCT02219711
What this trial is testing

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Mirati Therapeutics Inc. 193
Not applicableActive Not RecruitingNCT06780384
What this trial is testing

NTRK 1,2,3 Rearrangements in Patients With Solid Tumors

Who this might be right for
NTRK1/2/3 Fusion Gene Detection
Federico Cappuzzo 5,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03834961
What this trial is testing

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Who this might be right for
Central Nervous System NeoplasmInfantile FibrosarcomaRecurrent Acute Leukemia+2 more
Children's Oncology Group 33
Early research (Phase 1)Study completedNCT02122913
What this trial is testing

Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 75
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Testing effectiveness (Phase 2)Looking for participantsNCT06010342
What this trial is testing

Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Who this might be right for
Solid Tumor
Teligene US 60
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Load More Results